Oncogeni: fattori di crescita
|
|
- Duane Wright
- 8 years ago
- Views:
Transcription
1 Oncogeni: fattori di crescita
2 Oncogeni: recettori per fattori di crescita
3 Oncogeni: trasduttori del segnale
4 Oncogeni: fattori trascrizionali
5 Meccanismo di azione degli oncogeni 2 recettore 2 per il fattore di crescita epidermico umano 1 3 proto-oncogene (c-sis; sis = simian sarcoma) 4
6 Analisi del trascrittoma
7 Schematic illustration of the role of cyclins CDKs, and cyclin-dependent kinase inhibitors in regulating the G1/S cell-cycle transition. External signals activate multiple signal transduction pathways, including those involving the MYC and RAS genes, which lead to synthesis and stabilization of cyclin D (there are several D cyclins, but, for simplification, we refer to them as "cyclin D"). Cyclin D binds to CDK4, forming a complex with enzymatic activity (cyclin D can also bind to CDK6, which appears to have a similar role as CDK4). The cyclin D-CDK4 complex phosphorylates RB, located in the E2F/DP1/RB complex in the nucleus, activating the transcriptional activity of E2F (E2F is a family of transcription factors, which we refer to as "E2F"), which leads to transcription of cyclin E, cyclin A and other proteins needed for the cell to go through the late G1 restriction point. The cell cycle can be blocked by the Cip/Kip inhibitors p21 and p27 (red boxes) and the INK4A/ARF inhibitors p16ink4a and p14arf (green boxes). Cell-cycle arrest in response to DNA damage and other cellular stresses is mediated through p53. The levels of p53 are under negative regulation by MDM2, through a feedback loop that is inhibited by p14arf.
8 Ciclo cellulare e punti di restrizione
9 Expression of cyclin-cyclin-dependent kinase (CDK) complexes during the cell cycle. The phases of the cycle are indicated inside the arrows.
10 Main Cell-Cycle Components and Their Inhibitors Cell-Cycle Component Cyclin-Dependent Kinases CDK4 CDK2 CDK1 Inhibitors Cip/Kip family: p21, p27 1NK4/ARF family: p16ink4a, p14arf Checkpoint Components p53 Ataxia-telangiectasia mutated (ATM) Main Function Forms a complex with cyclin D. The complex phosphorylates RB, allowing the cell to progress through the G 1 restriction point. Forms a complex with cyclin E in late G 1, which is involved in the G 1 /S transition. Forms a complex with cyclin A at the S phase that facilitates the G 2 /M transition. Forms a complex with cyclin B, which acts on the G 2 /M transition. Block the cell cycle by binding to cyclin-cdk complexes. p21 is induced by the tumor suppressor p53. p27 responds to growth suppressors such as transforming growth factor-β. p16ink4a binds to cyclin D-CDK4 and promotes the inhibitory effects of RB. p14arf increases p53 levels by inhibiting MDM2 activity. Tumor suppressor altered in the majority of cancers; causes cell-cycle arrest and apoptosis. Acts mainly through p21 to cause cell-cycle arrest. Causes apoptosis by inducing the transcription of pro-apoptotic genes such as BAX. Levels of p53 are negatively regulated by MDM2 through a feedback loop. p53 is required for the G 1 /S checkpoint and is a main component of the G 2 /M checkpoint. Activated by mechanisms that sense double stranded DNA breaks. Transmits signals to arrest the cell cycle after DNA damage. Acts through p53 in the G 1 /S checkpoint. At the G 2 /M checkpoint, it acts both through p53-dependent mechanisms and through the inactivation of CDC25 phosphatase, which disrupts the cyclin B-CDK1 complex. Component of a network of genes that include BRCA1 and BRCA2, which link DNA damage with cell-cycle arrest and apoptosis.
11 Inherited Predisposition to Cancer Inherited Cancer Syndromes (Autosomal Dominant) RB p53 p16ink4a APC Gene Retinoblastoma Inherited Predisposition Li-Fraumeni syndrome (various tumors) Melanoma Familial adenomatous polyposis/colon cancer NF1, NF2 Neurofibromatosis 1 and 2 BRCA1, BRCA2 Breast and ovarian tumors MEN1, RET Multiple endocrine neoplasia 1 and 2 MSH2, MLH1, MSH6 PATCH Familial Cancers Hereditary nonpolyposis colon cancer Nevoid basal cell carcinoma syndrome Familial clustering of cases, but role of inherited predisposition not clear for each individual Breast cancer Ovarian cancer Pancreatic cancer Inherited Autosomal Recessive Syndromes of Defective DNA Repair Xeroderma pigmentosum Ataxia-telangiectasia Bloom syndrome Fanconi anemia neoplasie cutanee alta frequenza nella rottura e nel riarrangiamento dei cromosomi
12 Patogenesi del retinoblastoma (locus RB su cromosoma 13q14) Patologia oculare, e rappresenta il tumore maligno con maggiore diffusione in età pediatrica
13 Trasformazione neoplastica e controllo della morte cellulare: p53 The Growth Arrest and DNA Damageinducible 45 (GADD45) proteins have been implicated in regulation of many cellular functions including DNA repair, cell cycle control, senescence and genotoxic stress
14 METASTASI I A tappa Perdita delle giunzioni intercellulari 1) Molecole di adesione intercellulare (adesione omotipica) Caderina E (catenine) Integrine 2) Perdita dell inibizione da contatto 3) Perdita della polarità cellulare Perdita di espresisone di Caderina E promuove epithelial mesenchymal transition (EMT)
15 Ruolo di APC nella regolazione della stabilità e della funzione della β-catenina C-MYC, ciclina D1 Epithelial-mesenchymal transition (EMT) is a program of development of biological cells characterized by loss of cell adhesion, repression of E.cadherin expression, and increased cell mobility
16 Virus oncogeni nell uomo
17 Virus oncogeni e microambiente tumorale
18 Azione di cancerogeni inizianti e promuoventi
19 Tappe nello sviluppo di un carcinoma del colon Molecular model for the evolution of colorectal cancers through the adenoma-carcinoma sequence. Although APC mutation is an early event and loss of p53 occurs late in the process of tumorigenesis, the timing for the other changes may show variations.
20 Selected Oncogenes, Their Mode of Activation, and Associated Human Tumors Category Protooncogene Mode of Activation Associated Human Tumor Growth Factors PDGF-βchain SIS Overexpression Astrocytoma Osteosarcoma Fibroblast growth factors HST-1 INT-2 Overexpression Amplification Stomach cancer Bladder cancer Breast cancer Melanoma TGFα TGFα Overexpression Astrocytomas Hepatocellular carcinomas HGF HGF Overexpression Thyroid cancer Growth Factor Receptors EGF-receptor family ERB-B1 (ECFR) ERB-B2 Overexpression Amplification Squamous cell carcinomas of lung, gliomas Breast and ovarian cancers CSF-1 receptor FMS Point mutation Leukemia Receptor for neurotrophic factors RET Point mutation Multiple endocrine neoplasia 2A and B, familial medullary thyroid carcinomas PDGF receptor PDGF-R Overexpression Gliomas Receptor for stem cell (steel) factor KIT Point mutation Gastrointestinal stromal tumors and other soft tissue tumors Proteins Involved in Signal Transduction GTP-binding K-RAS H-RAS N-RAS Point mutation Point mutation Point mutation Colon, lung, and pancreatic tumors Bladder and kidney tumors Melanomas, hematologic malignancies Nonreceptor tyrosine kinase ABL Translocation Chronic myeloid leukemia Acute lymphoblastic leukemia RAS signal transduction BRAF Point mutation Melanomas WNT signal transduction β-catenin Point mutation Overexpression Hepatoblastomas, hepatocellular carcinoma Nuclear Regulatory Proteins Transcriptional activators C-MYC N-MYC L-MYC Translocation Amplification Amplification Burkitt lymphoma Neuroblastoma, small cell carcinoma of lung Small cell carcinoma of lung Cell-Cycle Regulators Cyclins CYCLIN D CYCLIN E Translocation Amplification Overexpression Mantle cell lymphoma Breast and esophageal cancers Breast cancer Cyclin-dependent kinase CDK4 Amplification or point mutation Glioblastoma, melanoma, sarcoma
21 Oncosoppressori nefroblastoma,
22 Geni caretaker e gatekeeper
23 Geni caretaker e gatekeeper Caretaker Genes: Geni di riparazione Stabilità genomica. Es.: BRCA-1, BRCA-2 Necessari piu eventi gatekeeper Genes: Regolano ingresso In un percorso di oncogenesi es.: RB, p53 Necessario un evento Schematic illustration of the pathways of malignancy initated by mutation of the gatekeeper genes (e.g., APC, NF-1, RB) or caretaker genes (e.g., hmsh2, BRCA-1, BRCA-2)
24 Trasformazione neoplastica e controllo della morte cellulare
25 Effetti delle proteine virali HPV E6 e HPV E7 sul ciclo cellulare papilloma virus umano: papillomi e carcinomi squamosi Effect of HPV proteins E6 and E7 on the cell cycle. E6 and E7 enhance p53 degradation, causing a block in apoptosis and decreased activity of the p21 cell cycle inhibitor. E7 associates with p21 and prevents its inhibition of the Cyclin/CDK4 complex; E7 can bind to RB, removing cell cycle restriction. The net effect of HPV E6 and E7 proteins is to block apoptosis and remove the restrains to cell proliferation
26 Traslocazioni e attivazione di oncogeni Imatinib
27 Sindromi neoplastiche ereditarie
Molecular Basis of Cancer
Molecular Basis of Cancer The literature on the molecular basis of cancer continues to proliferate at such a rapid pace that it is easy to get lost in the growing forest of information. We list some fundamental
More informationLesson 3 Reading Material: Oncogenes and Tumor Suppressor Genes
Lesson 3 Reading Material: Oncogenes and Tumor Suppressor Genes Becoming a cancer cell isn t easy One of the fundamental molecular characteristics of cancer is that it does not develop all at once, but
More informationContents. molecular biology techniques. - Mutations in Factor II. - Mutations in MTHFR gene. - Breast cencer genes. - p53 and breast cancer
Contents Introduction: biology and medicine, two separated compartments What we need to know: - boring basics in DNA/RNA structure and overview of particular aspects of molecular biology techniques - How
More informationIntroduction. Cancer Biology. Tumor-suppressor genes. Proto-oncogenes. DNA stability genes. Mechanisms of carcinogenesis.
Cancer Biology Chapter 18 Eric J. Hall., Amato Giaccia, Radiobiology for the Radiologist Introduction Tissue homeostasis depends on the regulated cell division and self-elimination (programmed cell death)
More informationTumor Suppressor Genes and Oncogenes: Genes that Prevent and Cause Cancer (Biochemistry/Molecular Biology Lecture)
Katherine M. Hyland, PhD, Tumor Suppressor Genes and Oncogenes: Genes that Prevent and Cause Cancer (Biochemistry/Molecular Biology Lecture) OBJECTIVES Describe the normal cellular functions of tumor suppressor
More informationA disease of populations of cells that live, divide, invade and spread without regard to normal limits
1 Targeted Cancer Therapies Mark McKeage Medical Oncology Specialist Professor in Clinical Pharmacology 2 Cancer Definition- A disease of populations of cells that live, divide, invade and spread without
More informationMolecular oncology: prospects for cancer diagnosis and therapy
Prof. Dr. Christoph Wagener Molecular oncology: prospects for cancer diagnosis and therapy In industrialised countries mortality from cancer has remained almost unchanged in recent decades, whereas mortality
More informationTypes of Cancers [-oma growth ]!
Cancer: disease of transcription factors and replication 1 Uncontrolled cell growth and division -> immortalized cells -> tumor growth -> metastasis (cells float away from tumor and spread throughout the
More informationOncogenes and Tumor Suppressor Genes
The International School of Advanced BioMedicine and Bioinformatics Catania [ Acitrezza ] - Italy 2007 Oncogenes and Tumor Suppressor Genes Pietro BUFFA Department of Biomedical Science University of Catania
More informationWhat is Cancer? Cancer is a genetic disease: Cancer typically involves a change in gene expression/function:
Cancer is a genetic disease: Inherited cancer Sporadic cancer What is Cancer? Cancer typically involves a change in gene expression/function: Qualitative change Quantitative change Any cancer causing genetic
More informationFarmacologia Chemioterapia_2
Farmacologia Chemioterapia_2 Principles of Cancer Treatment The goal of cancer treatment is first to eradicate the cancer. If this primary goal cannot be accomplished, the goal of cancer treatment shifts
More informationLa diagnostica molecolare nelle neoplasie colo-rettali. A do Scarpa. U iversita di Vero a
La diagnostica molecolare nelle neoplasie colo-rettali C-NET A do Scarpa e Dipartime to Pato ogia e U iversita di Vero a La stessa malattia puo avere diverse patogenesi cucchiaio moneta forchetta Gastrointestinal
More informationDepartment of BioScience Technology Chung Yuan Christian University 2015/08/13
Department of BioScience Technology Chung Yuan Christian University 2015/08/13 Cancer Cells Cancer, the 1st leading cause of death, is an example of a disease that arises from abnormalities in cell function
More informationOncogenes and Cancer B-1
Oncogenes and Cancer B-1 Figure 30.1 The frequency of newly diagnosed cancers increases sharply with age. Each point on the graph gives the incidence over a one year period for the preceding age group
More informationBIOLOGY REDISCOVERING. Cell Biology and Cancer. Molecular to Global Perspectives. Introduction
REDISCOVERING BIOLOGY Molecular to Global Perspectives We now understand a lot about cancer. We know that it results from a series of genetic changes having to do with cell division and growth control
More informationMédecine de précision médecine personnalisée en Oncologie. Fabien Calvo, Directeur Recherche et Innovation, INCa, Directeur ITMO Cancer, AVIESAN
Médecine de précision médecine personnalisée en Oncologie Fabien Calvo, Directeur Recherche et Innovation, INCa, Directeur ITMO Cancer, AVIESAN Successful targeted drug development Rapid identification
More informationMolecular Human Genetics. Cancer, Tumor suppressor genes, Oncogenes
Youtube ARCC http://www.youtube.com/watch?v=3pobqrfz0no It's Our Time - American Association for Cancer Research (AACR) Molecular Human Genetics Cancer, Tumor suppressor genes, Oncogenes Hum 2014/15 1
More information4.2 Cellular responses to chemotherapeutic agents: Apoptosis, cell cycle arrest, and mitotic catastrophe
4. Introduction 11 4. INTRODUCTION 4.1 Colorectal cancer Colorectal cancer (CRC) is one of the most common forms of human malignancy especially in industrialized countries, and is the second largest cause
More informationCommon Cancers & Hereditary Syndromes
Common Cancers & Hereditary Syndromes Elizabeth Hoodfar, MS, LCGC Regional Cancer Genetics Coordinator Kaiser Permanente Northern California Detect clinical characteristics of hereditary cancer syndromes.
More informationDeregolazione dei sistemi di controllo nella cellula neoplastica
1 Lezioni Dipartimento di Oncologia Farmacologia Molecolare Deregolazione dei sistemi di controllo nella cellula neoplastica Massimo Broggini 20 febbraio 2006, 2 Unlimited replicative potential Defective
More information# Circuits relevant to cancer, related to known TFs.
# Circuits relevant to cancer, related to known TFs. # Final dataset of circuits where at least one gene has been annotated as relevant to cancer. # Circuits correspond to blocks separated by a symbol.
More informationNew Hampshire Childhood Cancer
Introduction: New Hampshire Childhood Cancer New Hampshire, Childhood Cancer, January 2009 Issue Brief Cancer in children is relatively uncommon, impacting fewer than twenty two of every 100,000 children
More informationSpecial report. Chronic Lymphocytic Leukemia (CLL) Genomic Biology 3020 April 20, 2006
Special report Chronic Lymphocytic Leukemia (CLL) Genomic Biology 3020 April 20, 2006 Gene And Protein The gene that causes the mutation is CCND1 and the protein NP_444284 The mutation deals with the cell
More informationThe Biological Basis of Cancer. Annie Young, Professor of Nursing, University of Warwick, University Hospitals Coventry and Warwickshire
The Biological Basis of Cancer Annie Young, Professor of Nursing, University of Warwick, University Hospitals Coventry and Warwickshire Aim of Presentation By the end of this presentation you will: Be
More informationLESSON 3.5 WORKBOOK. How do cancer cells evolve? Workbook Lesson 3.5
LESSON 3.5 WORKBOOK How do cancer cells evolve? In this unit we have learned how normal cells can be transformed so that they stop behaving as part of a tissue community and become unresponsive to regulation.
More informationGENETIC TESTING FOR INHERITED MUTATIONS OR SUSCEPTIBILITY TO CANCER OR OTHER CONDITIONS MED207.110
GENETIC TESTING FOR INHERITED MUTATIONS OR SUSCEPTIBILITY TO CANCER OR OTHER CONDITIONS MED207.110 COVERAGE: Pre- and post-genetic test counseling may be eligible for coverage in addition to the genetic
More informationCHAPTER 2: UNDERSTANDING CANCER
CHAPTER 2: UNDERSTANDING CANCER INTRODUCTION We are witnessing an era of great discovery in the field of cancer research. New insights into the causes and development of cancer are emerging. These discoveries
More informationCell Proliferation and Cancer
Geneticist: _Amit Singh Teacher: _Stanley C Hughes Cell Proliferation and Cancer Misconceptions: 1. Cancer does not come from outside but it is a transition of our own cells into cancerous cells. 2. Cancer
More informationCancer SBL101. James Gomes School of Biological Sciences Indian Institute of Technology Delhi
Cancer SBL101 James Gomes School of Biological Sciences Indian Institute of Technology Delhi All Figures in this Lecture are taken from 1. Molecular biology of the cell / Bruce Alberts et al., 5th ed.
More informationMutations: 2 general ways to alter DNA. Mutations. What is a mutation? Mutations are rare. Changes in a single DNA base. Change a single DNA base
Mutations Mutations: 2 general ways to alter DNA Change a single DNA base Or entire sections of DNA can move from one place to another What is a mutation? Any change in the nucleotide sequence of DNA Here
More informationPublikationsliste Claudia Götz
Publikationsliste Claudia Götz 1. Reinhard,B., Götz, C., and Faillard, H.: Synthesis of N-Acetyl-9-Oacetylneuraminic acid α-p-aminophenylthioketoside and its application as ligand in the affinity chromatography
More informationMolekylært målrettet medicinsk kræftbehandling for klinikere principper og metoder
Molekylært målrettet medicinsk kræftbehandling for klinikere principper og metoder Professor Claus Lindbjerg Andersen Department of Molecular Medicine (MOMA) Aarhus University hospital Outline The central
More informationNuovi Scenari in Oncologia. G. Zoppoli X-Files in Nutrizione Clinica e Artificiale, 08/06/2012
Nuovi Scenari in Oncologia G. Zoppoli X-Files in Nutrizione Clinica e Artificiale, 08/06/2012 WHAT is cancer? «Cancer is a genetic disease of the somatic cell» [B. Vogelstein] Ten years ago Now [Cell.
More informationUpdate in Hematology Oncology Targeted Therapies. Mark Holguin
Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning
More informationNotch 1 -dependent regulation of cell fate in colorectal cancer
Notch 1 -dependent regulation of cell fate in colorectal cancer Referees: PD Dr. Tobias Dick Prof. Dr. Wilfried Roth http://d-nb.info/1057851272 CONTENTS Summary 1 Zusammenfassung 2 1 INTRODUCTION 3 1.1
More informationThe Diagnosis of Cancer in the Pathology Laboratory
The Diagnosis of Cancer in the Pathology Laboratory Dr Edward Sheffield Christmas Select 74 Meeting, Queen s Hotel Cheltenham, 3 rd December 2014 Agenda Overview of the pathology of cancer How specimens
More informationNew strategies in anticancer therapy
癌 症 診 療 指 引 簡 介 及 臨 床 應 用 New strategies in anticancer therapy 中 山 醫 學 大 學 附 設 醫 院 腫 瘤 內 科 蔡 明 宏 醫 師 2014/3/29 Anti-Cancer Therapy Surgical Treatment Radiotherapy Chemotherapy Target Therapy Supportive
More informationSuccesses and Limitations of Targeted Therapies in Renal Cell Carcinoma
g Tumor Res. Basel, Karger, 2014, vol 41, pp 98 112 (DOI: 10.1159/000355906) Successes and Limitations of Targeted Therapies in Renal Cell Carcinoma Marc Pracht Dominik Berthold Medical Oncology Unit,
More informationDal germinale al somatico nella identificazione di tumori ereditari
Modena 18-19 novembre 2010 Dal germinale al somatico nella identificazione di tumori ereditari Laura Ottini Tendencies to develop cancer can be inherited Fletcher & Houlston, 2010 Cancer is a genetic disease
More information4.1 3T12 and 312 are immortalized cell lines with transforming potential:
DISCUSSION CHAPTER 4 4.1 3T12 and 312 are immortalized cell lines with transforming potential: Transformation of a normal cell with finite number of divisions into a tumorigenic cell of potentially infinite
More informationSecond Cancers in Adults
Second Cancers in Adults This document focuses on second cancers in adults. For information about second cancers after treatment of childhood cancers, see our document Children Diagnosed With Cancer: Late
More informationWhat is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals
What is New in Oncology Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals Personalized Medicine Personalized Genomics Genomic Medicine Precision Medicine Definition Application
More informationTest Information Sheet
Test Information Sheet GeneDx 207 Perry Parkway Gaithersburg, MD 20877 Phone: 888-729-1206 Fax: 301-710-6594 E-mail: wecare@genedx.com www.genedx.com/oncology OncoGene Dx: High/Moderate Risk Panel Sequence
More informationWhat is cancer? Cancer. Properties of cancer cells. Properties of cancer cells. Cancer continued; three cancer types. When good cells go bad
What is cancer? Cancer When good cells go bad Caner is defined as the continuous uncontrolled growth of cells. A tumor is a any abnormal proliferation of cells. Benign tumors stays confined to its original
More informationGenes and Cancer. What are genes? Dominant vs. recessive genes
Genes and Cancer Advances in science have improved our knowledge of the inner workings of cells, the basic building blocks of the body. All living things are made of cells. Complex animals such as humans
More informationMUTATION, DNA REPAIR AND CANCER
MUTATION, DNA REPAIR AND CANCER 1 Mutation A heritable change in the genetic material Essential to the continuity of life Source of variation for natural selection New mutations are more likely to be harmful
More informationNumero stimato delle varie forme di tumore nel 1997 (US)
chi la fa l aspetti Numero stimato delle varie forme di tumore nel 1997 (US) Mortality-cancer type Mortality and incidence-time National cancer institute US Una base genetica per il cancro Stato canceroso
More informationThe Biochemistry of Cancer Additional readings; pp. 682 (oncogenes); pp. 680 (Ras) ; and 916 (P53 and apoptosis)
The Biochemistry of Cancer Additional readings; pp. 682 (oncogenes); pp. 680 (Ras) ; and 916 (P53 and apoptosis) Introduction: Cancer cells are characterized by three distinguishing properties: 1) a diminished
More informationSommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle
Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle TITLE PROJET NOM HOPITAL Assessment of tumor angiogenesis using PET/CT with 18 F-Galacto- RGD. (PNC_29_001) Division of
More informationFulfilling the Promise
Fulfilling the Promise Advancing the Fight Against Cancer: America s Medical Schools and Teaching Hospitals For more than a century, the nation s medical schools and teaching hospitals have worked to understand,
More informationExelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference
Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference Two New Clinical Programs and Significant Expansion of Cancer Pipeline Planned for 2004 SOUTH SAN FRANCISCO, Calif., Jan. 13 /PRNewswire-FirstCall/
More informationWhite paper Evaluation of BRAF (V600E) Mutation by Immunohistochemical Staining with anti-braf V600E (VE1) Antibody: A Comparison with Sanger
White paper Evaluation of BRAF (V600E) Mutation by Immunohistochemical Staining with anti-braf V600E (VE1) Antibody: A Comparison with Sanger Sequencing 2 Evaluation of BRAF (V600E) Mutation by Immunohistochemical
More information4/15/2013. bi/o carcin/ chem/o immun/o onc/o radi/o sarc/o. anabrachydysectoendoneo- -ectomy -genesis -oma -plasia -sarcoma
Chapter Sixteen Oncology bi/o carcin/ chem/o immun/o onc/o radi/o sarc/o Combining Forms Prefixes and Suffixes Carcinogenesis anabrachydysectoendoneo- -ectomy -genesis -oma -plasia -sarcoma Causes of cancer
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
More informationDevelopments in Biomarker Identification and Validation for Lung Cancer
Developments in Biomarker Identification and Validation for Lung Cancer Alexandre Passioukov, MD, PhD Alexandre.Passioukov@eortc.be Contents Introduction Lung cancer pathogenesis NSCLC treatment options
More informationLEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials
LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials OUR FOCUS ABOUT emerging treatments Presentation for: Judith E. Karp, MD Advancements for Acute Myelogenous Leukemia Supported by an unrestricted educational
More informationS1 Text. Modeling deterministic single-cell microrna-p53-mdm2 network Figure 2 Figure 2
S1 Text. Modeling deterministic single-cell microrna-p53-mdm2 network The schematic diagram of the microrna-p53-mdm2 oscillator is illustrated in Figure 2. The interaction scheme among the mrnas and the
More information7.012 Quiz 3 practice
MIT Biology Department 7.012: Introductory Biology - Fall 2004 Instructors: Professor Eric Lander, Professor Robert A. Weinberg, Dr. Claudette Gardel 7.012 Quiz 3 practice Quiz 3 on Friday, November 12th
More informationCancerTREATMENT NGS+ NSCLC Summary Report Page 1 of 7 PATIENT SPECIMEN PHYSICIAN
Page 1 of 7 POSITIVE TEST RESULTS Biomarker Result DETECTED NEGATIVE TEST RESULTS FDA Approved Therapies Targeting Molecular Pathway TEST DESCRIPTION: CancerTREATMENT NGS+ uses Next Generation Sequencing
More informationPHARMA SCIENCE MONITOR AN INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES APOPTOSIS IS A NEWER TARGET FOR LUNGS CANCER
PHARMA SCIENCE MONITOR AN INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES APOPTOSIS IS A NEWER TARGET FOR LUNGS CANCER 1 Trivedi Upama N*., 2 Trivedi Naitik D., 3 Patel Madhubhai M., 4 Patel Jayvadan
More informationtreatments) worked by killing cancerous cells using chemo or radiotherapy. While these techniques can
Shristi Pandey Genomics and Medicine Winter 2011 Prof. Doug Brutlag Chronic Myeloid Leukemia: A look into how genomics is changing the way we treat Cancer. Until the late 1990s, nearly all treatment methods
More informationCyclin-Dependent Kinases and CDC7 as Therapeutic Targets
Cyclin-Dependent Kinases and CDC7 as Therapeutic Targets Geoffrey Shapiro, M.D., Ph.D. Dana-Farber Cancer Institute Gary K. Schwartz, M.D. Columbia University Disclosures Geoffrey Shapiro, MD, PhD Advisory
More informationBiochemistry of Cancer Cell
Biochemistry of Cancer Cell Prof. Taha Kumosani Prof. Taha Kumosani http://biochemistry4all.com/taha/5.htm Cancer: an Overview Paleopathologists Dinosaur bones Egyptians Papyrus Autopsis Hippocrates Carcinoma
More informationGenetic Testing for Familial Adenomatous Polyposis and MYH-Associated Polyposis (Lynch Syndrome)
Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance
More informationCancer can occur at almost any organ in the body
Cancer can occur at almost any organ in the body There are many different types of cancers affecting different parts of the body. A cancer, or tumor, can occur in any organ or tissue of the human body.
More informationTargeted therapies in hereditary cancer with PARP-inhibitors: a new biological approach.
AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA Targeted therapies in hereditary cancer with PARP-inhibitors: a new biological approach. PARP Antonio Frassoldati Dept Oncology, Hematology and Lung diseases
More informationComplex Systems BioMedicine: Molecules, Signals, Networks, Diseases
The International School of Advanced Molecular BioMedicine Complex Systems BioMedicine: Molecules, Signals, Networks, Diseases AciTrezza (Catania), Italy, October 2nd-6th, 2009 Hieronymus Bosch: Garden
More informationPART 3.3: MicroRNA and Cancer
BIBM 2010 Tutorial: Epigenomics and Cancer PART 3.3: MicroRNA and Cancer Dec 18, 2010 Sun Kim at Indiana University Outline of Part 3.3 Background on microrna Role of microrna in cancer MicroRNA pathway
More informationThis presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking
Q1/2016 This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking statements involve risks and uncertainties
More informationFuture Oncology: Technology, Products, Market and Service Opportunities
Brochure More information from http://www.researchandmarkets.com/reports/296370/ Future Oncology: Technology, Products, Market and Service Opportunities Description: Future Oncology is an analytical newsletter
More informationGenetics and Breast Cancer. Elly Lynch, Senior Genetic Counsellor Manager, Austin Health Clinical Genetics Service
Genetics and Breast Cancer Elly Lynch, Senior Genetic Counsellor Manager, Austin Health Clinical Genetics Service Overview Background/Our Team What is the difference between sporadic/familial cancer? How
More informationPublic-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics
EPAAC WP8 Research Forum - 2 July, Sofitel Hotel Europe, Brussels Public-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics JY Blay, Past President EORTC
More informationMOH Policy for dispensing NEOPLASTIC DISEASES DRUGS
MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS All prescriptions for antineoplastic drugs must be accompanied by the MOH special form. All the attachments mentioned on this form shall be submitted
More informationMEDICAL POLICY POLICY TITLE
Original Issue Date (Created): July 1, 2002 Most Recent Review Date (Revised): Effective Date: April 15, 2008 July 1, 2009- RETIRED I. DESCRIPTION/BACKGROUND High dose chemotherapy (HDC) involves the administration
More informationThe Genetics of Early- Onset Breast Cancer. Cecelia Bellcross, Ph.D., M.S.,C.G.C. Department of Human Genetics Emory University School of Medicine
The Genetics of Early- Onset Breast Cancer Cecelia Bellcross, Ph.D., M.S.,C.G.C. Department of Human Genetics Emory University School of Medicine All cancers are genetic BUT Not all cancers are hereditary
More informationCancer causes about one-fifth of the deaths in the
23 ANER A blood smear from a person with acute myelogenous leukemia. The gigantic cells with irregularly shaped purple nuclei are leukemia cells. The small reddish-gray circular cells are normal red blood
More informationTumour Markers. What are Tumour Markers? How Are Tumour Markers Used?
Dr. Anthony C.H. YING What are? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer cells or
More informationWILLIAM N. ROM, JOHN G. HAY, THEODORE C. LEE, YIXING JIANG, and KAM-MENG TCHOU-WONG
State of the Art Molecular and Genetic Aspects of Lung Cancer WILLIAM N. ROM, JOHN G. HAY, THEODORE C. LEE, YIXING JIANG, and KAM-MENG TCHOU-WONG Division of Pulmonary and Critical Care Medicine, Departments
More informationmicrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved
microrna 2 micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved Regulate gene expression by binding complementary regions at 3 regions of target mrnas Act as negative
More informationUnderstanding series. new. directions. 1-800-298-2436 LungCancerAlliance.org. A guide for the patient
Understanding series LUNG CANCER: new treatment directions 1-800-298-2436 LungCancerAlliance.org A guide for the patient TABLE OF CONTENTS What s New in lung cancer? Advancements...4 Changes in genes that
More informationName of Policy: Genetic Testing for Inherited Cancer Predisposition and/or Pharmacogenetics related to Cancer Treatment
Name of Policy: Genetic Testing for Inherited Cancer Predisposition and/or Pharmacogenetics related to Cancer Treatment Policy #: 133 Latest Review Date: April 2015 Category: Laboratory Policy Grade: D
More informationRegulation of Protein Translation and c-jun expression by Prostate Tumor Overexpressed1 (PTOV1)
Regulation of Protein Translation and c-jun expression by Prostate Tumor Overexpressed1 (PTOV1) Verónica Cánovas, PhD Student Laboratory of Cell Signalling and Cancer Progression, Dra. Rosanna Paciucci
More informationLung Cancer Research: From Prevention to Cure (Video Transcript)
Lung Cancer Research: From Prevention to Cure (Video Transcript) To view the accompanying video of this transcript and to download a PDF of the physician's slide presentation, visit: http://www.uchospitals.edu/specialties/cancer/lung/video/index.html
More informationFor years, drug developers have used histology as the
NOVEL Clinical Trial Designs in oncology: An Histology-Independent Approach Cancer s heterogeneity is a leading reason why product development in this therapeutic area is so risky and costly and why the
More informationIf and when cancer cells stop dividing, they do so at random points, not at the normal checkpoints in the cell cycle.
Cancer cells have escaped from cell cycle controls Cancer cells divide excessively and invade other tissues because they are free of the body s control mechanisms. Cancer cells do not stop dividing when
More informationHormones & Chemical Signaling
Hormones & Chemical Signaling Part 2 modulation of signal pathways and hormone classification & function How are these pathways controlled? Receptors are proteins! Subject to Specificity of binding Competition
More informationLeukemia Research Foundation 2004-2005 Scientific Research Grant Recipients
Page 1 of 5 NEW INVESTIGATOR AWARDS Ioannis Aifantis, Ph.D. The University of Chicago, Chicago, IL $75,000.00 Cooperation of Notch and pre-tcr Signaling in the Induction of T Cell Leukemia The pre-t Cell
More informationName of Policy: Genetic Testing for Inherited Cancer Predisposition and/or Pharmacogenetics related to Cancer Treatment
Name of Policy: Genetic Testing for Inherited Cancer Predisposition and/or Pharmacogenetics related to Cancer Treatment Policy #: 133 Latest Review Date: April 2015 Category: Laboratory Policy Grade: D
More informationUnderstanding the Molecular and Cellular Biology of Endocrine-Related Cancers. Mont Ste. Odile, Alsace, France 11-14 September 2008
33 rd European Symposium on Hormones and Cell Regulation Understanding the Molecular and Cellular Biology of Endocrine-Related Cancers Mont Ste. Odile, Alsace, France 11-14 September 2008 Invited Speakers:
More informationGenetic Testing for Lynch Syndrome/Colorectal Cancer and Polyposis Syndromes
Genetic Testing for Lynch Syndrome/Colorectal Cancer and Polyposis Syndromes Policy Number: Original Effective Date: MM.02.007 09/01/2011 Line(s) of Business: Current Effective Date: HMO; PPO 09/01/2011
More informationLecture 11 The Cell Cycle and Mitosis
Lecture 11 The Cell Cycle and Mitosis In this lecture Cell division Chromosomes The cell cycle Mitosis PPMAT Apoptosis What is cell division? Cells divide in order to reproduce themselves The cell cycle
More informationThis module consists of four units which will provide the user a basic knowledge of cancer as a disease.
Module 5: What is Cancer? This module consists of four units which will provide the user a basic knowledge of cancer as a disease. After completing this module, cancer abstractors will be able to: Define
More informationCytoSelect 48-Well Cell Adhesion Assay (ECM Array, Colorimetric Format)
Product Manual CytoSelect 48-Well Cell Adhesion Assay (ECM Array, Colorimetric Format) Catalog Number CBA-070 CBA-070-5 48 assays 5 x 48 assays FOR RESEARCH USE ONLY Not for use in diagnostic procedures
More informationFARMACI PERSONALIZZATI PER
ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI FONDAZIONE G. Pascale NAPOLI SC Biologia Cellulare e Bioterapie CENTRO RICERCHE ONCOLOGICHE MERCOGLIANO (AV) Laboratorio di Farmacogenomica FARMACI
More informationTargeted Therapies in Lung Cancer
Targeted Therapies in Lung Cancer I Edited by: Simona Carnio Thoracic Oncology Division - St Luigi Hospital Orbassano (TO) - Italy Silvia Novello Department of Oncology - University of Torino - Italy Why
More informationSystems Biology of Cancer: which pathways to choose? Emmanuel Barillot
Systems Biology of Cancer: which pathways to choose? Emmanuel Barillot Central questions to cancer On the clinical side: predict the phenotype On the biological side: explain tumorigenesis and tumoral
More informationEnhanced cytotoxicity of PARP inhibition in Mantle Cell Lymphoma harboring mutations in both ATM and p53
Manuscript EMM-2011-00864 Enhanced cytotoxicity of PARP inhibition in Mantle Cell Lymphoma harboring mutations in both ATM and p53 Chris T. Williamson, Eiji Kubota, Jeffrey D. Hamill, Alexander Klimowicz,
More informationImmunohistochemical differentiation of metastatic tumours
Immunohistochemical differentiation of metastatic tumours Dr Abi Wheal ST1. TERA 3/2/14 Key points from a review article written by Daisuke Nonaka Intro Metastatic disease is the initial presentation in
More informationCURRICULUM VITAE. Tabitha M. Hardy
CURRICULUM VITAE Tabitha M. Hardy Education: Doctor of Philosophy (Ph.D.), Microbiology and Immunology, Indiana University at Indiana University-Purdue University Indianapolis, Indianapolis, IN, 2004-2010
More informationNeoplasia gastrica cistica: GIST o leiomiosarcoma? Sebastiano Cacciaguerra U. O. Chirurgia Pediatrica Ospedale Garibaldi Catania
Neoplasia gastrica cistica: GIST o leiomiosarcoma? Sebastiano Cacciaguerra U. O. Chirurgia Pediatrica Ospedale Garibaldi Neoplasia gastrica cistica: GIST o leiomiosarcoma? Aims of presentation Atypical
More information